Literature DB >> 26183727

Drug safety aspects of herbal medicinal products.

T Wegener1, B Deitelhoff, A Silber-Mankowsky.   

Abstract

There are numerous statements in the literature suggesting that the safety of herbal products or herbal medicinal products is inadequately considered. Despite the presence of risk, the potential is commonly underestimated as herbals are considered to be natural substances. It is necessary to consider the different categories of herbal products in the market. On one hand there are authorised herbal medicinal products (HMPs) which have adhered to the requirements to present data on quality, efficacy and safety. On the other hand there are products falling outside the use of marketing authorisations as for remedies. In the European Union (EU), HMPs are subject to an ambitious and comprehensive risk management system as for chemically defined drugs, which react effectively to risk concerns with scientific methods, as has been shown in the past. The established methods of pharmacovigilance and risk management favour the authorisation of herbal preparations for medicinal purposes as proprietary medicinal drugs.

Mesh:

Substances:

Year:  2015        PMID: 26183727     DOI: 10.1007/s10354-015-0370-9

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  32 in total

1.  Current Issues Regarding Complementary and Alternative Medicine (CAM) in the United States: Part 2: Regulatory and Safety Concerns and Proposed Governmental Policy Changes with Respect to Dietary Supplements.

Authors:  C Lee Ventola
Journal:  P T       Date:  2010-09

Review 2.  Intellectual property protection in the natural product drug discovery, traditional herbal medicine and herbal medicinal products.

Authors:  Murat Kartal
Journal:  Phytother Res       Date:  2007-02       Impact factor: 5.878

Review 3.  Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment.

Authors:  Scott A Jordan; David G Cunningham; Robin J Marles
Journal:  Toxicol Appl Pharmacol       Date:  2009-12-16       Impact factor: 4.219

Review 4.  The quality of commercially available herbal products.

Authors:  Priya Ruparel; Brian Lockwood
Journal:  Nat Prod Commun       Date:  2011-05       Impact factor: 0.986

5.  Use and safety perception of herbal remedies in patients with liver/biliary tract disorders: an Italian study.

Authors:  Massimo Marignani; Sara Gallina; Michela Di Fonzo; Ilaria Deli; Paola Begini; Elia Gigante; Marcella Epifani; Stefano Angeletti; Gianfranco Delle Fave
Journal:  J Clin Gastroenterol       Date:  2010-09       Impact factor: 3.062

6.  Fatal kavalactone intoxication by suicidal intravenous injection.

Authors:  Raimo A Ketola; Jenni Viinamäki; Ilpo Rasanen; Anna Pelander; Sirkka Goebeler
Journal:  Forensic Sci Int       Date:  2015-02-02       Impact factor: 2.395

7.  Evidence based medicine: what it is and what it isn't.

Authors:  D L Sackett; W M Rosenberg; J A Gray; R B Haynes; W S Richardson
Journal:  BMJ       Date:  1996-01-13

8.  Risks associated with herbal medicinal products.

Authors:  E Ernst; M H Pittler
Journal:  Wien Med Wochenschr       Date:  2002

9.  Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases.

Authors:  Rolf Teschke; Alexander Schwarzenboeck; Karl-Heinz Hennermann
Journal:  Eur J Gastroenterol Hepatol       Date:  2008-12       Impact factor: 2.566

Review 10.  Underestimating the toxicological challenges associated with the use of herbal medicinal products in developing countries.

Authors:  Vidushi S Neergheen-Bhujun
Journal:  Biomed Res Int       Date:  2013-09-19       Impact factor: 3.411

View more
  1 in total

1.  Safety Evaluation of a New Traditional Chinese Medical Formula, Ciji-Hua'ai-Baosheng II Formula, in Adult Rodent Models.

Authors:  Biqian Fu; Xiangyang Zhai; Shengyan Xi; Lifeng Yue; Yanan Wang; Yingkun Qiu; Yuewen Gong; Yangxinzi Xu; Linchao Qian; Jingru Huang; Dawei Lu; Shuqiong Huang; Jing Wang; Jing Zhou; Di Wu; Yanhui Wang
Journal:  Evid Based Complement Alternat Med       Date:  2019-01-14       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.